Logo image of IXHL

INCANNEX HEALTHCARE INC (IXHL) Stock Fundamental Analysis

NASDAQ:IXHL - Nasdaq - US45333F1093 - Common Stock - Currency: USD

0.3389  +0.1 (+43.6%)

Fundamental Rating

2

IXHL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. IXHL has a bad profitability rating. Also its financial health evaluation is rather negative. IXHL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IXHL has reported negative net income.
In the past year IXHL has reported a negative cash flow from operations.
IXHL had negative earnings in each of the past 5 years.
In the past 5 years IXHL always reported negative operating cash flow.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

IXHL's Return On Assets of -214.35% is on the low side compared to the rest of the industry. IXHL is outperformed by 91.71% of its industry peers.
Looking at the Return On Equity, with a value of -2466.94%, IXHL is doing worse than 84.46% of the companies in the same industry.
Industry RankSector Rank
ROA -214.35%
ROE -2466.94%
ROIC N/A
ROA(3y)-117.62%
ROA(5y)-108.95%
ROE(3y)-146.83%
ROE(5y)-135.42%
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K

1.3 Margins

IXHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for IXHL remains at a similar level compared to 1 year ago.
IXHL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -22.90, we must say that IXHL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IXHL (-22.90) is worse than 82.90% of its industry peers.
IXHL has a Debt/Equity ratio of 3.90. This is a high value indicating a heavy dependency on external financing.
IXHL has a Debt to Equity ratio of 3.90. This is amonst the worse of the industry: IXHL underperforms 82.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.9
Debt/FCF N/A
Altman-Z -22.9
ROIC/WACCN/A
WACCN/A
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

IXHL has a Current Ratio of 1.80. This is a normal value and indicates that IXHL is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.80, IXHL is not doing good in the industry: 64.77% of the companies in the same industry are doing better.
IXHL has a Quick Ratio of 1.80. This is a normal value and indicates that IXHL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.80, IXHL is doing worse than 61.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.8
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.01% over the past year.
Measured over the past years, IXHL shows a very strong growth in Revenue. The Revenue has been growing by 49.63% on average per year.
EPS 1Y (TTM)64.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-79.08%
Revenue growth 5Y49.63%
Sales Q2Q%N/A

3.2 Future

IXHL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -63.44% yearly.
Based on estimates for the next years, IXHL will show a very strong growth in Revenue. The Revenue will grow by 860.90% on average per year.
EPS Next Y-116.51%
EPS Next 2Y-63.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2538.49%
Revenue Next 2Y860.9%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 200K 400K 600K 800K 1M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IXHL. In the last year negative earnings were reported.
Also next year IXHL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as IXHL's earnings are expected to decrease with -63.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IXHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (7/15/2025, 3:38:08 PM)

0.3389

+0.1 (+43.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)09-26 2025-09-26
Inst Owners8.29%
Inst Owner Change0%
Ins Owners13.03%
Ins Owner Change0%
Market Cap9.97M
AnalystsN/A
Price TargetN/A
Short Float %18.91%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1321.88%
Min EPS beat(2)-1352.83%
Max EPS beat(2)-1290.92%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-32.64%
Revenue NY rev (3m)-32.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.77
P/FCF N/A
P/OCF N/A
P/B 10.34
P/tB 10.34
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.35%
ROE -2466.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-117.62%
ROA(5y)-108.95%
ROE(3y)-146.83%
ROE(5y)-135.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 3.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.8
Altman-Z -22.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
EPS Next Y-116.51%
EPS Next 2Y-63.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-79.08%
Revenue growth 5Y49.63%
Sales Q2Q%N/A
Revenue Next Year2538.49%
Revenue Next 2Y860.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-109.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.64%
OCF growth 3YN/A
OCF growth 5YN/A